Inventor · disambiguated record
Jay Copeland Strum
Also filed as: STRUM JAY C · STRUM JAY COPELAND
53 granted patents·36 pending applications·808 citations·filing 2001–2025
99Inventor score
Files withG1 THERAPEUTICS INC75PHARMACOSMOS HOLDING AS5DIROCCO DEREK P1INCYCLIX BIO LLC1SHARPLESS NORMAN E1
Top patents by PatentIndex Score
89 records- 0199US10189850B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2018·Granted Jan 29, 2019·17 cites·1 claims
- 0299US10189849B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2018·Granted Jan 29, 2019·18 cites·1 claims
- 0399US10189851B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2018·Granted Jan 29, 2019·19 cites·1 claims
- 0499US9499564B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2015·Granted Nov 22, 2016·34 cites·2 claims
- 0599US9481691B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2015·Granted Nov 1, 2016·31 cites·2 claims
- 0699US9102682B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2014·Granted Aug 11, 2015·42 cites·16 claims
- 0799US8829012B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2014·Granted Sep 9, 2014·47 cites·47 claims
- 0899US8822683B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2014·Granted Sep 2, 2014·55 cites·37 claims
- 0999US8691830B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2013·Granted Apr 8, 2014·53 cites·42 claims
- 1099US8598197B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2013·Granted Dec 3, 2013·65 cites·58 claims
- 1199US8598186B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2013·Granted Dec 3, 2013·81 cites·24 claims
- 1298US11040042B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2020·Granted Jun 22, 2021·5 cites·2 claims
- 1398US10927120B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2020·Granted Feb 23, 2021·5 cites·3 claims
- 1498US10085992B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2016·Granted Oct 2, 2018·16 cites·9 claims
- 1598US10076523B2HSPC-sparing treatments for RB-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2016·Granted Sep 18, 2018·15 cites·15 claims
- 1698US9957276B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2016·Granted May 1, 2018·14 cites·57 claims
- 1798US9931345B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2016·Granted Apr 3, 2018·14 cites·20 claims
- 1898US9527857B2HSPC-sparing treatments for RB-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2014·Granted Dec 27, 2016·31 cites·74 claims
- 1998US9487530B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2014·Granted Nov 8, 2016·36 cites·50 claims
- 2098US9464092B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2014·Granted Oct 11, 2016·29 cites·54 claims
- 2197US11717523B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2021·Granted Aug 8, 2023·3 cites·21 claims
- 2297US11654148B2HSPC-sparing treatments for RB-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2021·Granted May 23, 2023·4 cites·16 claims
- 2397US10696682B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2018·Granted Jun 30, 2020·6 cites·12 claims
- 2497US10434104B2HSPC-sparing treatments for Rb-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2018·Granted Oct 8, 2019·7 cites·10 claims
- 2596US10925878B2HSPC-sparing treatments for RB-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2018·Granted Feb 23, 2021·5 cites·85 claims
- 2696US10709711B2Highly active anti-neoplastic and anti-proliferative agentsG1 THERAPEUTICS INC·Filed 2018·Granted Jul 14, 2020·6 cites·8 claims
- 2796US10660896B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2018·Granted May 26, 2020·5 cites·21 claims
- 2896US9717735B2Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2015·Granted Aug 1, 2017·16 cites·60 claims
- 2995US12168666B2Morphic forms of trilaciclib and methods of manufacture thereofG1 THERAPEUTICS INC·Filed 2021·Granted Dec 17, 2024·8 cites·27 claims
- 3095US11090306B2Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitorsG1 THERAPEUTICS INC·Filed 2019·Granted Aug 17, 2021·9 cites·6 claims
- 3195US10988479B1Morphic forms of trilaciclib and methods of manufacture thereofG1 THERAPEUTICS INC·Filed 2020·Granted Apr 27, 2021·15 cites·14 claims
- 3295US10981887B2Benzothiophene estrogen receptor modulatorsG1 THERAPEUTICS INC·Filed 2020·Granted Apr 20, 2021·3 cites·19 claims
- 3395US10966984B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2018·Granted Apr 6, 2021·5 cites·30 claims
- 3495US10413547B2Treatment of Rb-negative tumors using topoisomerase with cyclin dependent kinase 4/6 inhibitorsG1 THERAPEUTICS INC·Filed 2018·Granted Sep 17, 2019·11 cites·3 claims
- 3594US12285431B2Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitorsG1 THERAPEUTICS INC·Filed 2021·Granted Apr 29, 2025·2 cites·9 claims
- 3694US11357779B2G1T38 superior dosage regimesG1 THERAPEUTICS INC·Filed 2020·Granted Jun 14, 2022·7 cites·52 claims
- 3793US12364697B2G1T38 superior dosage regimesPHARMACOSMOS HOLDING AS·Filed 2022·Granted Jul 22, 2025·4 cites·18 claims
- 3893US11395821B2Treatment of EGFR-driven cancer with fewer side effectsG1 THERAPEUTICS INC·Filed 2019·Granted Jul 26, 2022·9 cites·7 claims
- 3992US10376519B2Tricyclic lactams for use in HSPC-sparing treatments for Rb-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2017·Granted Aug 13, 2019·5 cites·10 claims
- 4092US10231969B2Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat RB-positive tumorsG1 THERAPEUTICS INC·Filed 2017·Granted Mar 19, 2019·12 cites·13 claims
- 4191US11446295B2Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumorsG1 THERAPEUTICS INC·Filed 2019·Granted Sep 20, 2022·4 cites·6 claims
- 4291US10654831B2Antiproliferative pyrimidine-based compoundsG1 THERAPEUTICS INC·Filed 2018·Granted May 19, 2020·5 cites·19 claims
- 4390US10829490B2Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agentsG1 THERAPEUTICS INC·Filed 2018·Granted Nov 10, 2020·5 cites·29 claims
- 4489US10618905B2Pyrimidine-based compounds for the treatment of cancerG1 THERAPEUTICS INC·Filed 2018·Granted Apr 14, 2020·7 cites·20 claims
- 4589US2023381189A1Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4688US10633362B2Benzothiophene estrogen receptor modulatorsG1 THERAPEUTICS INC·Filed 2018·Granted Apr 28, 2020·2 cites·45 claims
- 4788US2023364098A1Hspc-sparing treatments for rb-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4887US11364222B2Combination therapy for treatment of cancerG1 THERAPEUTICS INC·Filed 2019·Granted Jun 21, 2022·7 cites·32 claims
- 4987US2024109906A1Cdk inhibitorsG1 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 5086US2025101030A1Morphic forms of trilaciclib and methods of manufacture thereofPHARMACOSMOS HOLDING AS·Filed 2024·Application pending·0 cites
Showing the top 50 of 89 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Jay Copeland Strum files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →